Global Opioid Induced Constipation Market Report and Forecast 2024-2032

Opioid Induced Constipation Market Report and Forecast 2024-2032


Opioid Induced Constipation Market Outlook

The market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, likely to be driven by increasing use of opioids, awareness and recognition, aging population, research and development, regulatory approvals.

Opioid Induced Constipation: Introduction

Opioid Induced Constipation (OIC) is one of the most common and debilitating side effects of opioid medications. Opioids, which are often prescribed for pain management, primarily work by binding to specific receptors in the brain to relieve pain. However, they also bind to opioid receptors in the gut, leading to a range of gastrointestinal side effects, with constipation being the most prevalent. While constipation may seem like a minor inconvenience, for those who experience it chronically due to opioid therapy, it can significantly impact their daily life and overall well-being. In some cases, OIC can lead to serious health complications, such as faecal impaction or bowel obstruction.

Treatment for OIC typically begins with lifestyle and dietary changes, including increasing fluid and fibre intake and engaging in regular physical activity. Over-the-counter treatments, like stool softeners and laxatives, are often the first line of pharmacological therapy. If these are ineffective, prescription drugs specifically designed to treat OIC may be considered. Some of these medications work by blocking the opioid effect on the gut without affecting its pain-relieving properties on the brain.

Key Trends in the Opioid Induced Constipation Market
  • Rising Opioid Consumption: With the increasing global prevalence of chronic pain conditions and subsequent rising opioid prescriptions, there's an associated rise in cases of OIC. This directly impacts the demand for OIC treatments.
  • Emergence of Targeted Therapies: There's been a shift from general laxatives to more targeted treatments specifically designed for OIC. Drugs such as naloxegol (Movantik), methylnaltrexone (Relistor), and lubiprostone (Amitiza) have received approval specifically for OIC treatment.
  • Direct-to-Consumer Advertising: Some pharmaceutical companies have taken to direct consumer advertising for OIC medications, making patients more aware of available treatments and potentially driving demand.
  • Patient Education and Awareness: There's a growing emphasis on educating patients about OIC when they are prescribed opioids. This proactive approach helps in early identification and management of OIC.
Opioid Induced Constipation Market Segmentations

The market can be categorised into disease type, drug class, route of administration, dosage form, distribution channel, end user, and region.

Market Breakup by Product
  • Mu-opioid Receptor Antagonists
  • Chloride Channel-2 Activators
  • Others
Market Breakup by Prescription Type
  • Over the Counter
  • Prescription
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Opioid Induced Constipation Market Overview

The opioid induced constipation (OIC) market revolves around the treatments and solutions developed to address the constipation caused by the use of opioids. As opioids continue to be a mainstay in pain management, especially in chronic conditions, the side effect of constipation has necessitated a distinct segment within the pharmaceutical market. Regulatory bodies like the FDA have given approvals to drugs specifically designed for OIC, validating the need for and importance of this market segment. The market is likely to see the entry of new drugs and treatments, given the continuous R&D focus.

Additionally, the global emphasis on personalized medicine might lead to more targeted and efficient OIC solutions. The North American market, particularly the United States, has been a significant player due to the high opioid prescription rates. Europe and parts of the Asia Pacific region, given their aging populations and increasing healthcare infrastructure, are also crucial regions for the OIC market.

Key Players in the Hemodialysis Vascular Grafts Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in opioid induced constipation market are as follows:
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • GSK Plc.
  • Bayer AG
  • Aurobindo Pharma
  • S.L.A. Pharma AG
  • Salix Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Opioid Induced Constipation Market Overview
3.1 Global Opioid Induced Constipation Market Historical Value (2017-2023)
3.2 Global Opioid Induced Constipation Market Forecast Value (2024-2032)
4 Global Opioid Induced Constipation Market Landscape
4.1 Global Opioid Induced Constipation Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Opioid Induced Constipation Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Prescription Type
5 Global Opioid Induced Constipation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Opioid Induced Constipation Market Segmentation
6.1 Global Opioid Induced Constipation Market by Product
6.1.1 Market Overview
6.1.2 Mu-opioid Receptor Antagonists
6.1.3 Chloride Channel-2 Activators
6.1.4 Others
6.2 Global Opioid Induced Constipation Market by Prescription Type
6.2.1 Market Overview
6.2.2 Over the Counter
6.2.3 Prescription
6.3 Global Opioid Induced Constipation Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacies
6.3.3 Retail Pharmacies
6.3.4 Online Pharmacies
6.3.5 Others
6.4 Global Opioid Induced Constipation Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Opioid Induced Constipation Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Opioid Induced Constipation Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Opioid Induced Constipation Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Opioid Induced Constipation Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Opioid Induced Constipation Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 F. Hoffmann-La Roche Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Mylan N.V.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Fresenius Kabi AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Hikma Pharmaceuticals PLC
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Novartis AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Teva Pharmaceutical Industries Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Bristol Myers Squibb Company
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 GSK Plc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Bayer AG
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Aurobindo Pharma
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 S.L.A. Pharma AG
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Salix Pharmaceuticals
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 Takeda Pharmaceutical Company Limited
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
18 Global Opioid Induced Constipation Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings